Key terms
About ZYME
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ZYME news
Mar 13
10:00am ET
Analysts’ Top Healthcare Picks: Zymeworks (ZYME), 89bio (ETNB)
Mar 12
6:25am ET
Zymeworks price target raised to $14 from $12 at Wells Fargo
Mar 12
5:16am ET
Buy Rating Affirmed for Zymeworks Amid Positive HERIZON Study Outlook and Robust Commercial Prospects of Zanidatamab
Mar 11
10:05pm ET
Stifel Nicolaus Keeps Their Buy Rating on Zymeworks (ZYME)
Mar 11
6:12am ET
Zymeworks price target raised to $10 from $8 at H.C. Wainwright
Mar 11
12:46am ET
Hold Rating on Zymeworks Amidst Pipeline Adjustments and Clinical Validation Awaited
Mar 08
1:01am ET
Zymeworks’ New Costs Risk – A Cause for Worry?
Mar 07
4:48pm ET
Zymeworks files to sell 5.09M shares of common stock for holders
Mar 07
11:32am ET
Zymeworks price target raised to $21 from $19 at Stifel
Mar 06
5:27pm ET
Zymeworks files to sell 5.09M shares of common stock for holders
Mar 06
5:08pm ET
Zymeworks Poised for Growth with Strong Cash Position
Mar 06
4:31pm ET
Zymeworks reports Q4 adjusted EPS (16c), consensus (43c)
Mar 05
5:07pm ET
Zymeworks Highlights Cancer Therapeutics at AACR
Feb 27
6:37am ET
Zymeworks to Present at Upcoming Health Conferences
Feb 22
4:40pm ET
Zymeworks Inc. Bolsters Board with Strategic New Director
Feb 09
4:52am ET
Zymeworks Inc Enhances Leadership and Governance Structure
Feb 09
4:52am ET
Zymeworks Inc Announces Board Appointments and Resignation
Jan 25
7:14am ET
Zentalis appoints Hausman as CMO, Rasbach as CBO
Jan 05
6:28am ET
Hold Rating on Zymeworks Amid Anticipation of Future Clinical Trial Outcomes
Jan 04
6:25am ET
Zymeworks sees cash runway sufficient into 2H 2027
Jan 04
6:04am ET
Zymeworks names Dr. Jeffrey Smith as Chief Medical Officer
Dec 28
11:14am ET
Biotech Alert: Searches spiking for these stocks today
Dec 28
11:14am ET
Biotech Alert: Searches spiking for these stocks today
Dec 26
8:07am ET
Zymeworks to sell 5.09M shares in $50M private placement
Dec 15
8:31am ET
Zymeworks added to Nasdaq Biotechnology Index
No recent news articles are available for ZYME
No recent press releases are available for ZYME
ZYME Financials
Key terms
Ad Feedback
ZYME Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ZYME Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range